What Праджисан treats: main uses and benefits

Праджисан is utilized to provide hormone support in specific clinical scenarios where a deficiency in natural progesterone levels is identified. The primary uses are centered on reproductive health, including support for luteal phase defects and functioning as an essential component during assisted reproductive technologies (ART), such as in vitro fertilization (IVF). The medication is intended to help establish and maintain a uterine environment conducive to the initial stages of pregnancy.

---

The treatment may also be recommended to help manage certain gynecological symptoms, including those associated with premenstrual syndrome (PMS) and particular forms of menstrual irregularities. By addressing the underlying hormonal situation, the medication may contribute to an improvement in related physical and emotional discomfort. The overall goal is to support the body's physiological processes.

Quick Fact: Relief for Physical and Emotional Discomfort (The medication may help mitigate discomfort associated with certain menstrual cycle variations.)

Who Can and Cannot Use Праджисан?

Eligibility for Праджисан is strictly defined by regulatory documentation, focusing on patient health status and developmental stage. The medicine is primarily intended for adult women of reproductive age who require hormonal support, such as for luteal phase deficiency in Assisted Reproductive Technology (ART).

---

Absolute Contraindications

The medicine must not be used by individuals with the following high-risk conditions, as they constitute absolute regulatory prohibitions:

• A history of active arterial or venous thromboembolism (blood clots).
• Severe hepatic impairment or disease (severe liver function issues).
• Known or suspected malignancy of the breast.
• Undiagnosed abnormal genital bleeding.

Conditional Use and Restrictions

Use is not indicated in the pediatric population, as safety and efficacy are not established. For the geriatric population, use is often not intended for women 65 years and older. The medicine is permitted and indicated for use in the first trimester for luteal support, but is otherwise contraindicated for non-indicated uses during established pregnancy. Additionally, close monitoring is required for patients with a history of depression, and caution is advised for those with renal dysfunction.

Interactions with other medicines and products

This section outlines the clinically significant drug-drug and drug-product interactions documented in the official labeling for progesterone products.

Interacting Medicinal Product Categories

Category	Interaction Mechanism and Effect	Regulatory Requirement
Strong CYP3 A4 Inducers (e.g., rifampin, carbamazepine, phenytoin)	These drugs increase the activity of the liver enzyme CYP3 A4, which metabolizes progesterone. This results in significantly decreased plasma concentrations of progesterone.	The combination may lead to a loss of progesterone's required effect and is generally avoided.
Strong CYP3 A4 Inhibitors (e.g., ketoconazole, clarithromycin, ritonavir)	These drugs inhibit the CYP3 A4 enzyme, reducing progesterone clearance. This results in significantly increased plasma concentrations of progesterone.	Use with caution and/or avoidance is required due to the potential for increased drug exposure and associated effects.
Other Vaginal Products	Products such as antifungal treatments, vaginal lubricants, diaphragms, or condoms.	Co-administration is not recommended for certain dosage forms (e.g., vaginal gels/inserts) as they may alter the intended release and absorption of progesterone from the medicinal product.

Official Interaction Notes

The most significant pharmacokinetic constraint documented in regulatory labeling involves medicines that strongly induce or inhibit the CYP3 A4 enzyme pathway, which is the primary route for progesterone metabolism. Specifically, inducers increase the rate of elimination, while inhibitors decrease it, leading to the opposite effect on drug exposure in the body. Although not explicitly listed as a contraindication for all progesterone products, official documentation also mandates considering the risk of additive QTc prolongation when this drug is co-administered with other medicines known to affect cardiac repolarization, ensuring a comprehensive assessment of pharmacodynamic risk.

Праджисан is formulated progesterone, a steroid hormone, and acts as an agonist at the intracellular Progesterone Receptors (PR), specifically the PR-A and PR-B isoforms, located in the nucleus and cytoplasm of target cells in tissues such as the uterus, central nervous system, and mammary glands.

Upon intracellular binding, the ligand-receptor complex undergoes dimerization and translocates into the nucleus. This complex then binds to specific DNA sequences known as Progesterone Response Elements (PREs) in the promoter regions of target genes. This molecular interaction modulates gene transcription, leading to either upregulation or downregulation of protein synthesis.

Downstream cascades include secretory transformation of the endometrium and inhibition of myometrial smooth muscle contractility. In the central nervous system, progesterone can also act via metabolites as a positive allosteric modulator of the GABA A receptor, leading to modulation of neuronal excitability. The system-level physiological consequence is the maintenance of a quiescent uterine environment and regulated changes in reproductive tract tissues.

Administration Guidelines for Progesterone (Праджисан)

Progesterone may be administered via the oral or vaginal route, with the specific route and dose depending on the prescribed regimen.

---

Administration Scope

Feature	Oral Route (Capsules)	Vaginal Route (Soft Capsules)
Route of Administration	Oral	Vaginal
Dosing Schedule	200–300 mg daily, divided into one or two doses.	200–600 mg daily, divided into one or two doses.
Timing/Condition	Preferably taken at bedtime. Must be taken without food to control absorption.	Inserted deep into the vagina. Often administered in the morning and at bedtime.
Missed Dose Rule	Take the dose as soon as remembered, unless it is near the time for the next dose. Do not take a double dose.

---

Procedural Structure

Step Sequence:

• Step 1: Verify the prescribed route and dosage (e.g., 100 mg or 200 mg). For oral use, ensure the stomach is empty.
• Step 2 (Oral): Swallow the capsule(s) whole with water, preferably at bedtime.
• Step 2 (Vaginal): Insert the soft capsule(s) deep into the vagina as prescribed (e.g., once or twice daily).
• Step 3: Maintain the established daily schedule. If a dose is missed, resume the schedule without doubling the next dose.

---

Connection to the Overall Use Protocol:

Administration of micronized progesterone involves a daily, timed dosing regimen, requiring adherence to either an oral or vaginal delivery method. The protocol emphasizes consistent daily timing and the correct relation to food intake for the oral route to ensure predictable systemic absorption, and deep placement for the vaginal route. Dosing for either route must be continuous throughout the period determined by the specific therapeutic protocol.

Research evidence / Overview of studies for Праджисан

---

Evidence for use in Regulating Menstrual Cycles

This section will summarize the evidence from clinical studies, including controlled and observational studies, that have evaluated this medicine in conditions characterized by fluctuating or episodic manifestations such as irregular or absent menstrual periods in premenopausal women.

Research has evaluated this medicine in women experiencing an absence of menstruation. These studies monitored the return of a menstrual period, which is an outcome reflecting daily functioning or activity level. The findings describe patterns observed in the studies where a menstrual period was observed in some studies following treatment. While studies explored the short-term return of cycles, the long-term effects are not fully established once the medicine is stopped.

Evidence for use in Preventing Uterine Lining Thickening (Endometrial Hyperplasia)

This section will outline the research that examined the use of this medicine in relation to the lining of the uterus (endometrium) becoming overly thick in postmenopausal women who are also taking estrogen therapy.

This medicine was evaluated in trials where women, typically postmenopausal, were receiving separate estrogen treatment, and the research examined whether combining the two was associated with a lower occurrence of changes in the uterine lining. Findings indicate that when used alongside estrogen, research examined whether its use was associated with patterns related to the appearance or thickness of the uterine lining. The follow-up durations were limited in many of these studies, meaning that the evidence focuses primarily on short-to-medium-term observations.

---

Long-term Studies and Follow-up

Research exploring extended use of this medicine focuses on outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort. Currently, evidence is limited regarding the very long-term outcomes and the durability of the responses. The data are still emerging in this area, and long-term effects are not fully established. Comparative evidence is lacking with other treatment approaches over longer timeframes.

What is still uncertain about Праджисан

A number of key areas still require further research. Evidence quality varies across studies, and for some less-common scenarios, findings were mixed or inconsistent. This research provides insight into short-term changes but not all aspects of its use are fully understood. For conditions characterized by fluctuating or episodic manifestations, more data are needed from studies conducted during periods of increased symptom activity. The available research does not determine whether an individual will respond similarly to the group patterns reported in the studies.

Key Studies & References

1. Progestogens and endometrial protection - British Menopause Society Consensus Statement
2. Secondary Amenorrhea - StatPearls (Source for treatment goal in anovulation/PCOS)
3. Management of Endometrial Hyperplasia - Royal College of Obstetricians and Gynaecologists (RCOG) Guideline

Common questions about Праджисан (FAQ)

Q: Can Pradzhisan cause weight gain?

Official product information indicates that changes in body weight, including both increases and decreases, have been reported as a possible adverse reaction associated with the use of this medicine. Individual physiological responses may vary, and official labels advise noting any unexpected or significant changes during use.

Q: How soon does Pradzhisan start working?

According to pharmacokinetic data found in regulatory documents, the maximum concentration of the hormone in the blood is typically reached about 2 to 3 hours after taking the medicine orally. It is important to note that vaginal administration may result in different absorption profiles and timings than the oral route.

Q: Does Pradzhisan affect blood test results?

Regulatory documents note that progesterone may influence the results of certain laboratory tests. This potential effect is specifically mentioned in relation to tests used to measure endocrine system function and liver function.

Q: Is Pradzhisan compatible with alcohol?

Official warnings indicate that alcohol consumption is generally not recommended while using this medicine. Alcohol may interfere with how the liver metabolizes the hormone and can potentially worsen central nervous system effects such as drowsiness and dizziness.

Q: Does Pradzhisan interact with birth control pills?

Official product information notes that interactions can occur with other medicines that affect the CYP450 enzyme system, which processes hormones. Because contraceptive pills contain hormones, taking them together with this medicine may potentially alter overall hormone levels in the body.

Q: Is Pradzhisan safe to use while breastfeeding?

Use of this medicine while breastfeeding is generally not recommended in official guidelines. This is because detectable amounts of the hormone are known to pass into human milk, and the possible effects on the infant remain clinically unknown, which supports the restriction.

Q: Why is Pradzhisan prescribed to men?

The approved uses for this medicine focus on conditions related to female reproductive function, such as luteal phase support in assisted reproductive technology or hormonal replacement therapy. Official regulatory documents do not list specific approved indications for its use in men.

Q: Can Pradzhisan cause an allergic reaction?

Yes, official safety information notes a risk of hypersensitivity and allergic reactions. For individuals with a known allergy or hypersensitivity to the ingredients, regulatory documents state the medicine should not be used.

Q: Does Pradzhisan raise or lower blood pressure?

Official product labels do not typically list blood pressure changes as a common side effect of this medicine alone. However, caution is advised for individuals with uncontrolled hypertension, and high blood pressure has been noted as a possible serious effect in studies involving combined hormonal therapies.

Q: How does Pradzhisan interact with herbal supplements?

Interactions may occur with herbal products that influence the liver enzymes responsible for processing this medicine, particularly the CYP3A4 pathway. For example, some regulatory information notes that herbal supplements like St. John’s Wort may increase the rate at which progesterone is broken down, potentially reducing its expected effect.

Q: What happens if I suddenly stop taking Pradzhisan?

When the medicine is stopped, withdrawal bleeding (a period-like event) may occur in some treatment protocols, such as when it is used to regulate menstrual cycles. For other uses, the specific treatment protocol dictates the necessary time and manner of discontinuation to maintain the required hormonal environment.

Q: Is Pradzhisan a prescription drug or can it be bought over the counter?

Official documentation confirms that micronized progesterone soft capsules are generally classified as a prescription-only medicine in most regulated markets. Its classification as prescription-only means it is not available for purchase without a valid prescription.

Q: Can one travel and fly during Pradzhisan use?

The official safety information notes a risk of thromboembolic events (blood clots) associated with this medicine. During periods of prolonged immobilization, such as long-distance travel or flights, precautions related to blood clot risk may need to be considered.

Q: How often should I get blood tests while taking Pradzhisan?

Official monitoring recommendations note that the required frequency of lab tests is determined by the specific treatment plan and protocol. Close observation may be advised for individuals with certain pre-existing conditions, such as a history of depression, diabetes, or those at risk for fluid retention.

Q: Does Pradzhisan affect the thyroid gland?

Official product information advises that thyroid function should be monitored in women who are also taking thyroid replacement hormone therapy. The use of progesterone, especially in combination with other hormones, may influence thyroid levels in the body.

Q: Can Pradzhisan lower libido?

Official regulatory documents list changes in libido (sex drive) as a possible adverse reaction associated with the use of progestin medicines like this one.

Q: How can Pradzhisan affect vision?

Official safety warnings describe that sudden changes in vision, such as partial or complete loss of vision, bulging eyes, or double vision, are considered serious events. Official warnings classify the occurrence of these or other signs of retinal vascular lesions (eye blood vessel issues) as a serious safety concern that requires immediate medical evaluation.

Official Storage and Disposal Instructions for Pradzhisan (Progesterone)

Storage Requirements

Pradzhisan (micronized progesterone capsules) must be stored at controlled room temperature, specifically between 20^circmathrmC and 25^circmathrmC (68^circmathrmF and 77^circmathrmF). The product must be protected from moisture and excessive heat and should not be frozen.

Storage Constraint	Requirement
Temperature	20^circmathrmC to 25^circmathrmC
Container	Keep in the original packaging
Child Safety	Store out of the sight and reach of children

Disposal Requirements

Unused or expired Pradzhisan must be handled as pharmaceutical waste. Do not dispose of the capsules in household trash or by flushing them down the sink or toilet (wastewater). Disposal must follow local regulatory procedures, typically by returning the product to a pharmacy or designated collection point.